Top-Selling GLP-1 Medications Globally

Eli Lilly's tirzepatide (Mounjaro/Zepbound) and Novo Nordisk's semaglutide (Ozempic/Wegovy/Rybelsus) are the leading GLP-1 drugs, dominating the market with multi-billion dollar sales.

The top 3

  1. Bestselling GLP-1 for Diabetes Treatment: Eli Lilly's Mounjaro (tirzepatide) surged to become a top-selling diabetes drug, earning $22.965 billion in 2025 and surpassing its competitors.
  2. Leading GLP-1s for Weight Management: Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) are the leading GLP-1s for weight management, with Wegovy generating approximately $8.44 billion in 2024.
  3. Companies Dominating the GLP-1 Market: Eli Lilly and Novo Nordisk form a duopoly, leading the GLP-1 market with strong pipelines and commercial strategies, while other companies like Pfizer and Amgen are emerging.

Sources

Open the full topic